{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:52Z","timestamp":1788419872534,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Symptomatic treatment remains the cornerstone of therapeutic management in frontotemporal dementia (FTD), as disease-modifying therapies are currently unavailable. However, several medications originally developed for other neuropsychiatric conditions may represent potentially harmful medications (PHMs) in FTD. This study aimed to describe prescribing patterns following an FTD diagnosis and to evaluate the association between PHM exposure and hospital-based acute care (HBAC) utilization. We conducted a retrospective cohort study using TriNetX, a global health research network comprising clinical data from real-world settings. We included 179 individuals with an electronic health record (EHR)-recorded diagnosis of FTD from 43 healthcare organizations across the United States. Propensity-score matching balanced baseline characteristics, with propensity scores estimated by logistic regression. Risk ratios were calculated from observed event proportions in the matched cohorts, and time to first event was compared using Kaplan\u2013Meier estimates and a Cox proportional hazards model. Patients with at least one recorded PHM prescription after diagnosis formed the exposed cohort; those with none formed the unexposed cohort. The two cohorts were matched 1:1 using propensity scores to minimize confounding and to balance key demographic and clinical variables between groups. HBAC was defined as hospital inpatient or observation care, emergency department visits, or critical care services. Among the 179 individuals with FTD (mean age 67.9\u202f\u00b1\u202f14.9\u202fyears; 48.0% women), 71 (39.7%) were exposed to PHMs. After propensity-score matching, baseline characteristics were well balanced (56 patients per group). Overall, 39.7% of patients received at least one PHM, most commonly benzodiazepines (69.5%). In matched analyses, PHM exposure was associated with a significantly higher risk of HBAC [risk ratio (RR)\u202f=\u202f2.20; 95% confidence interval (CI), 1.35\u20133.57] and lower event-free survival (12.8% vs. 62.7%). This real-world study of post-diagnosis prescribing in FTD shows that PHM use is common and that a greater proportion of exposed patients experienced HBAC, with a shorter time to the first event; given residual confounding by indication, these findings are exploratory and hypothesis-generating rather than causal.<\/jats:p>","DOI":"10.3389\/fneur.2026.1930046","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:54:36Z","timestamp":1788418476000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform"],"prefix":"10.3389","volume":"17","author":[{"given":"Lorenza Pabst","family":"Botton","sequence":"first","affiliation":[{"name":"School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS)","place":["Porto Alegre, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Jacob","family":"Lazzaretti","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS)","place":["Porto Alegre, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lokschin","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS)","place":["Porto Alegre, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaderson Costa","family":"da Costa","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS)","place":["Porto Alegre, Brazil"]},{"name":"Department of Neurology, S\u00e3o Lucas Hospital of PUCRS","place":["Porto Alegre, Brazil"]},{"name":"Brain Institute of Rio Grande do Sul (BraIns)","place":["Porto Alegre, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[{"name":"Global Brain Health Institute, Memory and Aging Center, University of California, San Francisco","place":["San Francisco, CA, United States"]},{"name":"Department of Neurology, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas P.","family":"Schilling","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS)","place":["Porto Alegre, Brazil"]},{"name":"Department of Neurology, S\u00e3o Lucas Hospital of PUCRS","place":["Porto Alegre, Brazil"]},{"name":"Brain Institute of Rio Grande do Sul (BraIns)","place":["Porto Alegre, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano S.","family":"Aguzzoli","sequence":"additional","affiliation":[{"name":"Department of Neurology, S\u00e3o Lucas Hospital of PUCRS","place":["Porto Alegre, Brazil"]},{"name":"Brain Institute of Rio Grande do Sul (BraIns)","place":["Porto Alegre, Brazil"]},{"name":"Global Brain Health Institute, Memory and Aging Center, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1212\/WNL.0000000000004215","article-title":"Behavioral-variant frontotemporal dementia: distinct phenotypes with unique functional profiles","volume":"89","author":"O\u2019Connor","year":"2017","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNN.0000000000000217","article-title":"Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review","volume":"33","author":"Trieu","year":"2020","journal-title":"Cogn Behav Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jama.2021.1195","article-title":"Prevalence of central nervous system\u2013active polypharmacy among older adults with dementia in the US","volume":"325","author":"Maust","year":"2021","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trci.2017.10.008","article-title":"Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis","volume":"4","author":"Ramsey","year":"2018","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00228-015-1860-9","article-title":"The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries","volume":"71","author":"Renom-Guiteras","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40801-017-0123-8","article-title":"Potentially harmful medication use and decline in health-related quality of life among community-dwelling older adults","volume":"4","author":"Ie","year":"2017","journal-title":"Drugs Real World Outcomes"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1533317509356692","article-title":"Off-label medication use in frontotemporal dementia","volume":"25","author":"Hu","year":"2010","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3233\/JAD-230494","article-title":"Psychopharmacological medication use in frontotemporal dementia at the time of diagnosis: comparison with Alzheimer\u2019s disease","volume":"95","author":"Katisko","year":"2023","journal-title":"J Alzheimer's Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1533317513507375","article-title":"Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials","volume":"29","author":"Nardell","year":"2014","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5498\/wjp.v12.i2.298","article-title":"Associated mortality risk of atypical antipsychotic medication in individuals with dementia","volume":"12","author":"Phiri","year":"2022","journal-title":"World J Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/WNF.0000000000000469","article-title":"Behavioral and cognitive response to selective serotonin reuptake inhibitors in frontotemporal lobar degeneration: a systematic review and Meta-analysis","volume":"44","author":"Nisar","year":"2021","journal-title":"Clin Neuropharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4088\/JCP.v58n0506","article-title":"Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors","volume":"58","author":"Swartz","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jagp.2023.06.013","article-title":"Treatment efficacy of pharmacotherapies for frontotemporal dementia: a network meta-analysis of randomized controlled trials","volume":"31","author":"Huang","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2012.216219","article-title":"Use of hospital-based acute care among patients recently discharged from the hospital","volume":"309","author":"Vashi","year":"2013","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1176\/appi.neuropsych.21060166","article-title":"Advances in treatment of frontotemporal dementia","volume":"34","author":"Magrath Guimet","year":"2022","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.jamda.2021.12.038","article-title":"Sedation-associated medications at dementia diagnosis, their receptor activity, and associations with adverse outcomes in a large clinical cohort","volume":"23","author":"Mbazira","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1517\/14740338.3.5.485","article-title":"Safety of benzodiazepines in the geriatric population","volume":"3","author":"Madhusoodanan","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12916-020-01821-5","article-title":"Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study","volume":"18","author":"Richardson","year":"2020","journal-title":"BMC Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/tmj.2015.0008","article-title":"ATA practice guidelines for live, on-demand primary and urgent care","volume":"21","author":"Gough","year":"2015","journal-title":"Telemed J E-Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13311-023-01380-6","article-title":"New approaches to the treatment of frontotemporal dementia","volume":"20","author":"Neylan","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1533317514524813","article-title":"Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials","volume":"29","author":"Tampi","year":"2014","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.71079\/aside.im.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"Intern Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1930046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:54:36Z","timestamp":1788418476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1930046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":27,"alternative-id":["10.3389\/fneur.2026.1930046"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1930046","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1930046"}}